

REMARKS

Claims 1-2, 6-13, 17-29, 32-57, and 58-59, are pending for the Examiner's review and consideration. Applicants wish to correct the record with respect to a statement made in the previous amendment filed November 19, 2004, regarding the peptide Ac—D—Nal—D—Cpa—D—Pal—Ser—Tyr—D—Hci—Leu—Ilys—Pro—D—Ala—NH₂ recited in the claims. The undersigned recently learned that this peptide is well known in the art as teverelix, but it is not commercially available and is not a registered trademark. The specification has been amended accordingly. Applicants have amended the specification with regard to cetrorelix as well, which is also well known, but not a registered trademark.

Accordingly, it is believed that the entire application is now in condition for allowance, early notification of such would be appreciated. Should the Examiner not agree, a personal or telephonic interview is respectfully requested to discuss any remaining issues in order to expedite the eventual allowance of the claims.

Respectfully submitted,

1/21/05

Date

Jeffrey A. Wolfson
Jeffrey A. Wolfson (Reg. No. 42,234)

**WINSTON & STRAWN LLP
Customer Number: 28765**

(202) 371-5770